AI-generated summary
The authors studied whether applying topical brimonidine, an alpha-adrenergic receptor agonist, before laser treatment could reduce erythema and postinflammatory hyperpigmentation, which are common laser side effects, particularly in dark-skinned people. The abstract frames this as an investigation of a possible preventive approach, noting that no definitive strategy is currently known. The abstract does not report the outcome of the investigation in the portion provided.
- Who or what was studied
- Individuals receiving laser treatment, particularly dark-skinned individuals; the abstract does not state the number or characteristics of participants.
- Limits stated in the abstract
- The abstract provided does not report results, sample size, or study design, so the effectiveness of brimonidine cannot be assessed from it.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on tandfonline.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.